Jennison Associates LLC Decreases Stake in Insulet Corporation $PODD

Jennison Associates LLC reduced its position in Insulet Corporation (NASDAQ:PODD) by 55.2% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 108,354 shares of the medical instruments supplier’s stock after selling 133,363 shares during the period. Jennison Associates LLC’s holdings in Insulet were worth $34,043,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Zions Bancorporation National Association UT purchased a new position in Insulet in the 1st quarter valued at about $26,000. Larson Financial Group LLC lifted its position in shares of Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 81 shares during the last quarter. SouthState Corp increased its holdings in Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 76 shares during the last quarter. Kozak & Associates Inc. bought a new stake in Insulet in the second quarter valued at about $32,000. Finally, Trust Co. of Toledo NA OH bought a new stake in Insulet in the second quarter valued at about $35,000.

Insulet Price Performance

PODD opened at $311.95 on Friday. The firm has a market cap of $21.96 billion, a price-to-earnings ratio of 94.82, a price-to-earnings-growth ratio of 2.64 and a beta of 1.40. Insulet Corporation has a fifty-two week low of $227.03 and a fifty-two week high of $353.50. The company’s 50-day moving average price is $326.94 and its 200 day moving average price is $306.52. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet’s quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PODD. Leerink Partners boosted their price objective on Insulet from $339.00 to $355.00 and gave the company an “outperform” rating in a report on Tuesday, October 14th. Rothschild & Co Redburn boosted their price objective on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a report on Friday, October 3rd. Wells Fargo & Company boosted their price objective on Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a report on Friday, August 8th. Citigroup reissued a “buy” rating on shares of Insulet in a report on Tuesday, July 8th. Finally, Canaccord Genuity Group boosted their price objective on Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a report on Monday, September 29th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $352.11.

Insider Activity

In other Insulet news, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.